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Abstract: The graphene road in nanomedicine still seems very long and winding because the current
knowledge about graphene/cell interactions and the safety issues are not yet sufficiently clarified.
Specifically, the impact of graphene exposure on gene expression is a largely unexplored concern.
Herein, we investigated the intracellular fate of graphene (G) decorated with cyclodextrins (CD) and
loaded with doxorubicin (DOX) and the modulation of genes involved in cancer-associated canonical
pathways. Intracellular fate of GCD@DOX, tracked by FLIM, Raman mapping and fluorescence
microscopy, evidenced the efficient cellular uptake of GCD@DOX and the presence of DOX in the
nucleus, without graphene carrier. The NanoString nCounter™ platform provided evidence for 34
(out of 700) differentially expressed cancer-related genes in HEp-2 cells treated with GCD@DOX
(25 µg/mL) compared with untreated cells. Cells treated with GCD alone (25 µg/mL) showed
modification for 16 genes. Overall, 14 common genes were differentially expressed in both GCD and
GCD@DOX treated cells and 4 of these genes with an opposite trend. The modification of cancer
related genes also at sub-cytotoxic G concentration should be taken in consideration for the rational
design of safe and effective G-based drug/gene delivery systems. The reliable advantages provided
by NanoString® technology, such as sensibility and the direct RNA measurements, could be the
cornerstone in this field.
Int. J. Mol. Sci. 2020, 21, 4891; doi:10.3390/ijms21144891 www.mdpi.com/journal/ijms
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1. Introduction
In the last years, graphene-based materials (G) due to their outstanding physicochemical properties
have been proposed for promising biomedical/pharmaceutical applications, such as bio-imaging,
drug/gene delivery, and biomolecular detection [1–3]. Numerous studies have been dedicated to the
development and the biological response of G-based nanocarriers loaded with Doxorubicin (DOX),
an effective chemotherapeutic agent used for the treatment of different kind of cancer [4–6]. Generally,
literature data demonstrated superior therapeutic performance in cancer chemotherapy experiments,
both in vitro and in vivo, due to the improved tissue penetration and cellular uptake of G-based
nanocarriers [7,8]. However, the road of G in nanomedicine seems still very long and winding because
the current knowledge about the G/cell interactions and the safety issues are not yet sufficiently
clarified [9,10].
Pristine graphene (i.e., graphene in its original, unmodified form) has many remarkable properties
but it is unable to be dispersed in water, making exploitation of its unique features challenging and
less explored compared to its derivatives, that are more dispersible in aqueous medium, stable in
physiological conditions, and further tunable for a wide range of applications, due to host functional
groups [11,12]. G can differ on the basis of (i) synthetic approaches adopted for their preparation;
(ii) not being homogeneous nature (several oxidation states, different lateral sizes and number of layers,
colloidal stability, etc.); (iii) presence of impurities; (iv) nanocomposites obtained by combination with
organic or inorganic compounds. All these G have been clamped into the umbrella term of “graphene”
in the literature. The lack of univocal classification based on standardized characterization methods,
as well the wide range of assays and cell lines used for its biological evaluation, are the main causes of
the controversial literature reports about its safety issues [13].
In our ongoing program, aimed to the discovery of new G-based drug delivery systems [14–16],
we expand the aims of our work focusing our attention on the modulation of gene expression induced
by G-cell interaction. Differently from other nanomaterials, such as silica nanoparticles [17], the impact
of G exposure in gene expression is a concern largely unexplored, till now [18–21].
Herein, we focus our attention on the effects of exposure of human epithelial type 2 (HEp-2)
cells to GCD and GCD@DOX platforms (Figure 1). GCD is a functional graphene material, recently
synthesized in our lab [16] belonging to the “graphene-family materials and cyclodextrins” [22],
which was proposed as drug and/or gene carrier, due to its ability to avoid the entrapment in the
acidic lysosomes (characteristic of the clathrin-mediated route), versus the efficient caveolae-mediated
route [16]. GCD cellular uptake occurred via a specific caveolae-mediated endocytosis mechanism
inhibited by genistein (tyrosine-kinase inhibitor that affects caveolae dynamics) and unaffected by
filipin (inhibitor that sequesters cholesterol in the membrane and disrupts the lipid rafts) [16].
In this work, we used GCD to prepare GCD@DOX complex. Moreover, the changes in gene
expression involved in molecular pathways regulating cell cycle progression were investigated for
both GCD and GCD@DOX platforms. The physico-chemical properties of GCD and GCD@DOX
were investigated by Dynamic Light Scattering (DLS) and Zeta-potential measurements and
Raman spectroscopy. The intracellular trafficking of GCD@DOX was elucidated combining FLIM,
Raman imaging and fluorescent microscopy outcomes. Finally, the abilities of GCD and GCD@DOX
to induce changes in the expression of genes involved in processes associated to angiogenesis,
extracellular matrix (ECM) modification and tumor metastasis were evaluated using NanoString
nCounter™ platform, a novel digital molecular barcoding technology.
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Figure 1. (A) Doxorubicin (DOX); (B) Schematic sketch of Graphene functionalized with Cationic 
Cyclodextrins (GCD platform); (C) Schematic sketch of DOX loaded on GCD (GCD@DOX). 
2. Results 
2.1. Preparation and Characterization of GCD@DOX Complex 
Graphene modified with cationic cyclodextrins (GCD) was prepared according to our 
previously reported procedure [16]. DOX was loaded on GCD with high entrapment efficiency by 
mixing aqueous GCD dispersion and DOX solution under ultrasonication. GCD@DOX complex was 
characterized by spectroscopy, such as DLS, ζ-potential measurements and Raman. Overall 
properties of GCD and GCD@DOX were reported in Table 1. 
Table 1. Overall Properties of GCD and GCD@DOX in water. 
Sample 
DH (µm ± SD) 1,2 
(%) 3 
PDI 
 (mV ± 
SD) 
Theoretical 
Loading (%) 
3 Actual 
Loading (%) 
4 EE (%) 
GCD >1 μm  0.4 −9.5 + 0.3    
GCD@DOX 1 μm + 0.2  0.4 −16.6 + 4 2.6 2.5 95 
1 SD was calculated on three different batches. 2 Size with corresponding intensity % distribution. 3 
Actual loading is expressed as the amount of drug (mg) encapsulated per 100 mg of complex. 4 Ratio 
between actual and theoretical loading ×100. 
DLS and ζ-potential measurements were exploited to investigate the colloidal stability of 
GCD@DOX complex (Table 1). DLS analyses detected GCD and GCD@DOX as pseudo spherical 
large aggregates (DH ~1 μm) and no size changes were observed along the time. DLS values were not 
indicative of the morphology and size of the nanoplatform, but they assessed the average 
hydrodynamic size of large graphene sheet aggregates in diluted aqueous dispersion [23]. TEM 
micrographs showed graphene layers of about 400 nm with an average thickness of 10−12 nm [16]. 
DLS measurements indicated similar sizes between GCD and GCD@DOX aggregates; whereas, a 
decrease of the -potential value was detected for GCD@DOX (GCD about −9.5 mV vs. GCD@DOX 
about −16.6 mV). These findings indicated a higher colloidal stability of GCD@DOX complex in 
water compared to free GCD. The formation of GCD@DOX complex was further investigated by 
Raman spectroscopy (Figure 2). The Raman spectrum of GCD (spectrum a) showed the 
characteristic G (~1584 cm−1) and D (~1348 cm−1) graphene bands [24]; whereas, a more complex 
Raman profile was observed for GCD@DOX (Figure 2, spectrum b). Specifically, besides the typical 
G and D bands of graphene, a new weak band was evident at 1457 cm−1. This band was connected to 
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2. Results
2.1. Preparation and Characterization of GCD@DOX Complex
Graphene modified with cationic cyclodextrins (GCD) was prepared according to our previously
reported procedure [16]. DOX was loaded on GCD with high entrapment efficiency by mixing aqueous
GCD dispersion and DOX solution under ultrasonication. GCD@DOX complex was characterized
by spectroscopy, such as DLS, ζ-potential measurements and Raman. Overall properties of GCD and
GCD@DOX were reported in Table 1.
Table 1. Overall Properties of GCD and GCD@DOX in water.
Sample DH (µm ± SD)
1,2
(%) 3
PDI ζ (mV ± SD) TheoreticalLoading (%)
3 Actual
Loading (%)
4 EE (%)
GCD 1 µ ≥ 0.4 9.5 ± 0.3
GCD@DOX 1 µm ± 0.2 ≥ 0.4 −16.6 ± 4 2.6 2.5 95
1 S was calculated on three different batches. 2 Size with corresponding intensity % distribution. 3 Actual loading
is expressed as the amount of drug (mg) encapsulated per 100 mg of complex. 4 Ratio between actual and theoretical
loading ×100.
DLS and ζ-potential measurements were exploited to investigate the colloidal stability of
GCD@DOX complex (Table 1). DLS analyses detected GCD and GCD@DOX as pseudo spherical large
aggregates (DH ~1µm) and no size changes were observed along the time. LS values were not indicative
of the morphology and size of the nanoplatform, but they assessed the average hydrodynamic size of
large graphene sheet aggregates in diluted aqueous dispersion [23]. TEM micrographs showed graphene
layers of about 400 nm with an average thickness of 10–12 nm [16]. DLS measurements indicated similar
sizes between GCD and GCD@DOX aggregates; whereas, a decrease of the ζ-potential value was
detected for GCD@DOX (GCD about−9.5 mV vs. GCD@DOX about−16.6 mV). These findings indicated
a higher colloidal stability of GCD@DOX complex in water compared to free GCD. The formation
of GCD@DOX complex was further investigated by Raman spectroscopy (Figure 2). The Raman
spectrum of GCD (spectrum (a) showed the characteristic G (~1584 cm−1) and D (~1348 cm−1) graphene
bands [24]; whereas, a more complex Raman profile was observed for GCD@DOX (Figure 2, spectrum
(b). Specifically, besides the typical G and D bands of graphene, a new eak band was evident at
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1457 cm−1. This band was connected to that present at 1462 cm−1 (skeletal ring vibrations) in the
Raman spectrum of DOX (Figure 2, spectrum (c) [25]. Moreover, the Raman vibrational bands of GCD
and DOX overlapped with a broad band centered at around 2575 cm−1 (around 616 nm) attributed to
fluorescence emission of DOX. Taken together, these spectral differences clearly proved the interaction
between DOX and GCD due to the formation of GCD@DOX complex.
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2.2. Intracellular Trafficking of GCD@DOX by FLIM and Raman Mapping and Fluorescent Microscopy 
The intracellular trafficking of GCD@DOX was investigated by FLIM and Raman mapping 
using C26 colon carcinoma cells model. Owing to the intrinsic Raman signal of G nanoflakes, we 
employed confocal Raman microscopy to screen the uptake and localization of GCD@DOX inside 
live cells. This technique is a non-invasive analytical tool based on inelastic scattering of light by the 
molecules in a sample. A Raman spectrum provides information about the molecular composition, 
molecular structures, and molecular interactions in a sample. By scanning XY-plane areas of a 
sample at different z-depths and representing the intensity of selected Raman bands, one can 
construct a false-colored Raman map, which allows both the visual detection of the nanoagents 
inside cells and the identification of the biochemical profile of cellular constituents. The Raman map 
of a single C26 cancer cell was obtained by plotting the intensity of C-H stretching vibrational bands 
(2800–3100 cm−1) of lipids (Figure 3A). The visualization of GCD@DOX into C26 cancer cell was 
achieved by representing the intensity of the specific G band of graphene at 1584 cm−1 (Figure 3B). 
The overlaid Raman maps (Figure 3C) enabled the visual discrimination among nucleus, 
cytoplasmatic region and GCD@DOX. In particular, GCD@DOX can be seen as red spots inside the 
cytoplasm and around nucleus, suggesting that the GCD@DOX probably released DOX surrounding 
to the nucleus. The extracted Raman spectra corresponding to colored areas (Figure 3D) revealed 
obvious biochemical differences between red and blue areas. For instance, the Raman profile of the 
blue spectrum collected from the nucleus was dominated by the vibrational bands of cellular 
constituents at 2800–3100 cm−1 (lipids—stretching CH2), 1665 cm−1 (amide I—stretching CO coupled 
with deformation NH), 1453 cm−1 (lipids and proteins—deformation CH2, CH3), 1008 cm−1 
(phenylalanine—ring breathing) and 787 cm−1 (ring breathing DNA/RNA bases). In contrast, the red 
spectrum presented a hybrid Raman profile containing the spectral signal of graphene, cellular 
constituents and fluorescence emission of DOX. 
Figure 2. Ra a spectra of (a), GCD ( ) on dried droplets col ecte using an excitation
line at 532 n . tr f s li (c) recorded using the 785 n excitation line.
2.2. Intracellular Trafficking of GCD@DOX by FLIM and Raman Mapping and Fluorescent Microscopy
The intracellular trafficking of GCD@DOX was investigated by FLIM and Raman mapping
using C26 colon carcinoma cells model. Owing to the intrinsic Raman signal of G nanoflakes,
we employed confocal Raman microscopy to screen the uptake and localization of GCD@DOX
inside live cells. This technique is a non-invasive analytical tool based on inelastic scattering of
light by the molecules in a sample. A Raman spectrum provides information about the molecular
composition, molecular structures, and molecular interactions in a sample. By scanning XY-plane
areas of a sample at different z-depths and representing the intensity of selected Raman bands, one
can construct a false-colored Raman map, which allows both the visual detection of the nanoagents
inside cells and the identification of the biochemical profile of cellular constituents. The Raman map of
a single C26 cancer cell was obtained by plotting the intensity of C-H stretching vibrational bands
(2800–3100 cm−1) of lipids (Figure 3A). The visualization of GCD@DOX into C26 cancer cell was
achieved by representing the intensity of the specific G band of graphene at 1584 cm−1 (Figure 3B).
The overlaid Raman maps (Figure 3C) enabled the visual discrimination among nucleus, cytoplasmatic
region and GCD@DOX. In particular, GCD@DOX can be seen as red spots inside the cytoplasm and
around nucleus, suggesting that the GCD@DOX probably released DOX surrounding to the nucleus.
The extracted Raman spectra corresponding to colored areas (Figure 3D) revealed obvious biochemical
differences between red and blue areas. For instance, the Raman profile of the blue spectrum collected
from the nucleus was dominated by the vibrational bands of cellular constituents at 2800–3100 cm−1
(lipids—stretching CH2), 1665 cm−1 (amide I—stretching CO coupled with deformation NH), 1453 cm−1
(lipids and proteins—deformation CH2, CH3), 1008 cm−1 (phenylalanine—ring breathing) and 787 cm−1
(ring breathing DNA/RNA bases). In contrast, the red spectrum presented a hybrid Raman profile
containing the spectral signal of graphene, cellular constituents and fluorescence emission of DOX.
To confirm the cellular uptake of GCD@DOX, we invoked fluorescence lifetime imaging microscopy
(FLIM), an ideal technique for live-cell imaging, which is able to display the spatial distribution of
exited state lifetimes of a fluorophore, its molecule’s chemical microenvironment or different binding
state. Specifically, Figure 4A shows the FLIM image of the control C26 cancer cells, without therapeutic
agent. A slight autofluorescence signal emitted by the control cells can be observed with an average
lifetime value of about 4 ns (Figure 4B), due to the diversity of endogenous fluorophores and flavin
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coenzymes [26]. FLIM image in Figure 4D showed successfully internalization and cellular distribution
of the GCD@DOX inside C26 colon cells after 24 h of incubation having a shorter lifetimes value of
2.1 ns. Furthermore, by using the Andor spectrograph coupled to our Microtime 200 inverted FLIM
microscope, we were also able to collect the emission spectrum of the DOX loaded onto the GCD
inside the marked C26 colon cells from the bright-field microscopic image (Figure 4E). The emission
located at around 600 nm upon diode laser excitation at 485 nm (Figure 4E), confirming once again the
successful cellular internalization of GCD@DOX. Bright field image was shown in Figure 4C.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 5 of 20 
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Figure 3. Raman maps of a single C26 colon carcinoma cells incubated for 24 h with GCD@DOX.
(A) The map was obtained by plotting the intensity of C-H stretching vibrational bands of lipids at
2800–3100 cm−1 (B) The map was generated by plotting the intensity of the G band of graphene at
1584 cm−1. (C) Overlaid Raman maps presented in (A,B). (D) Extracted spectra corresponding to
colored areas.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 6 of 20 
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treated cells (red box) for 24 h of incubation (D), its corresponding lifetime histogram (F), and the 
recorded emission spectrum (E) inside the marked cell in (C). 
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Figure 5 represented HEp-2 cells untreated and treated with DOX and with GCD@DOX, 
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merged images. 
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patterns of cell distribution of DOX was visibly widespread in nuclear compartmentation, 
accordingly to doxorubicin-chromatin engagement reported in literature [27].  
Figure 4. FLIM image and its corresponding lifetime histogram (A,B) of the untreated C26 colon cancer
cells -as control, in comparison with the bright field (C) and FLIM image of the GCD@DOX treated
cells (red box) for 24 h of inc batio (D), its corresponding lifetime histogram (F), and the recorded
emission spectrum (E) inside the marked cell in (C).
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Finally, the intracellular fate of loaded and/or released DOX was visualized by confocal microscopy
images of HEp-2 cells exposed to GCD@DOX (25 µg/mL) for 24 h.
Figure 5 represented HEp-2 cells untreated and treated with DOX and with GCD@DOX, visualized
with DAPI filter (column A) to detect the nuclei, or visualized by Rhodamine filter (column B) to
visualize the natural red color of free and entrapped DOX. Column C represented the merged images.Int. J. Mol. Sci. 2020, 21, x FOR PEER REVIEW 7 of 20 
 
Figure 5. In vitro study of cellular uptake of GCD@DOX in HEp-2 cells. The HEp-2 cells were 
untreated or treated with GCD@DOX (25 μg/mL) and DOX (1.25 μg/mL). After 24 h the cells were 
harvested and the autofluorescence of GCD@DOX and DOX was evaluated through fluorescence 
analysis. A drop of mounting solution (ProLong™ Diamond Antifade Mountant with 
DAPI-Invitrogen p36971) was used for 30 min in a dark room for confocal microscopy analysis. 
Standard /DAPI/FITC/TRITC filters were used to detect the intracellular fluorescence. The column 
(A) represents untreated and treated cells with DOX and GCD@DOX and visualized with DAPI filter. 
The column (B) represents untreated and treated cells with DOX and GCD@DOX and visualized by 
Rhodamine filter. The (C) column represents the merged images. The images were captured and 
processed using Confocal laser scanning microscopy Leica TCS SP8 (Magnification, 63×). 
2.3. Cytotoxicity Study 
Cytotoxicity of GCD in different cell lines was investigated in our previous study [16]. 
Specifically, in tumor HEp-2 cells a cellular proliferation percentage of 75, 80 and 100% was detected 
after their exposition to graphene at 100, 50 and 25 μg/mL, respectively [16]. To complete the 
investigations on the cytotoxic effect of the whole drug delivery system (GCD@DOX), additional 
experiments (Figure 6) were performed by using free DOX (5, 2.5 and 1.25 μg/mL) and untreated 
HEp-2 cells as positive and negative controls, respectively. The cells were treated for 24 h with 
GCD@DOX at the concentrations of 100, 50 and 25 μg/mL corresponding to nominal DOX 
concentration of 2.5, 1.25 and 0.625 μg/mL, respectively. The results graphically represented as 
percentage of cell viability (Figure 6) showed a decrease of 40% and 76% of cellular proliferation 
after exposition to 100 and 50 μg/mL of GCD@DOX (DOX loading corresponding to 2.5 and 1.25 
μg/mL, respectively). These biological outcomes were comparable with the effects of free DOX at 5 
and 2.5 μg/mL that showed 40% and 88% of cellular proliferation (Figure 6). 
Fig re 5. In vitro study of cellular uptake of GCD@DOX in HEp-2 cells. The HEp-2 cells were untreated
or treated with GCD@DOX (25 µg/mL) and DOX (1.25 µg/mL). After 24 h the cells were harvested and
the autofluorescence of GCD@DOX and DOX was evaluated through fluorescence analysis. A drop of
mounting solution (ProLong™ Diamond Antifade Mountant with DAPI-Invitrogen p36971) was used
for 30 min in a dark room for confocal microscopy analysis. Standard /DAPI/FITC/TRITC filters were
used to detect the intracellular fluorescence. The column (A) represents untreated and treated cells with
DOX and GCD@DOX and visualized with DAPI filter. The column (B) represents untreated and treated
cells with DOX and GCD@DOX and visualized by Rhodamine filter. The (C) column represents the
merged images. The images were captured and processed using Confocal laser scanning microscopy
Leica TCS SP8 (Magnification, 63×).
The DAPI-Rhodamine overlapped images (column C) showed the perfect match between the
emitted red fluorescence of free DOX and GCD@DOX and the nuclei position (Figure 5). The patterns
of cell distribution of DOX was visibly widespread in nuclear compartmentation, accordingly to
doxorubicin-chro atin engagement reported in literature [27].
2.3. Cytotoxicity Study
Cytotoxicity of GCD in different cell lines was investigated in our previous study [16]. Specifically,
in tumor HEp-2 cells a cellular proliferation percentage of 75, 80 and 100% was detected after their
exposition to graphene at 100, 50 and 25 µg/mL, respectively [16]. To complete the investigations on
the cytotoxic effect of the whole drug delivery system (GCD@DOX), additional experiments (Figure 6)
were performed by using free DOX (5, 2.5 and 1.25 µg/mL) and untreated HEp-2 cells as positive and
negative controls, respectively. The cells were treated for 24 h with GCD@DOX at the concentrations
of 100, 50 and 25 µg/mL corresponding to nominal DOX concentration of 2.5, 1.25 and 0.625 µg/mL,
respectively. The results graphically represented as percentage of cell viability (Figure 6) showed a
decrease of 40% and 76% of cellular proliferation after exposition to 100 and 50 µg/mL of GCD@DOX
(DOX loading corresponding to 2.5 and 1.25 µg/mL, respectively). These biological outcomes were
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comparable with the effects of free DOX at 5 and 2.5 µg/mL that showed 40% and 88% of cellular
proliferation (Figure 6).
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Figure 6. In vitro study of the biocompatibility of GCD@DOX in HEp-2 cells. The data showed the % of
live cells compared to the control (free DOX at 5, 2.5 and 1.25 µg/mL) and cells only after 24 h. Cells were
exposed to 100, 50 and 25 µg/mL of GCD@DOX corresponding to 2.5, 1.25 and 0.625 µg/mL of loaded
DOX, respectively. The cellular proliferation index (%) was determined on the basis of ATP level using
ViaLight™ plus cell proliferation and cytotoxicity bioassay kit (Lonza Group Ltd., Basel, Switzerland)
in combination with GloMax Multi Microplate Luminometer, as described in Materials and Methods.
The GraphPad Prism 6 software was used for data analysis and for graphical representation. The assay
was performed as means of triplicates ± SD.
2.4. Gene Expression Modulation in HEp-2 Cells
The cancer transcriptome from control and treated HEp-2 cells was profiled using the NanoString
nCount r™ platform. We evaluated changes in the expression of genes involved in cesses a socia ed
to angiogenesis, extracellul r matrix modification (ECM) and tumor meta tasis induced by GCD and
GCD@DOX in HEp-2 cells at sub-toxic concentration (25 µg/mL). Al hough the ge e expression profile
control and treated cells was similar (Figure 7), the analysis r vealed a differential expression of
34 genes, 21 of which were d wn-regulated an 13 were up-regulated, in cells treated with GCD@DOX
in comparison to c trol cells (Table 2). In particular, gen s encoding for the proteins, such as
Matript s (ST14), Integrin-beta2 (ITGB2), Jagged 1 (JAG1), Amphiregulin (AREG), Cathepsin K (CTSK),
and Osteon ctin (SPARC) were expr ssed at very low levels as evidenced by the low raw count (below
100). Notably, all of these genes re related to tumorigenicity and tumor invasiven ss (Figur 7).
Among the highly expressed transcripts, the genes encoding for Gelsolin (GSN), Bone morphogene ic
protein 5 (BMP5) and Serine/Threonine Kinase 1 (AKT1) related to angiogenesis, ECM and metastasis
were down-regulated in GCD@DOX treated cells. At the same time, the transcript levels of genes
encodin for claudin-3 (CLDN3), the uclear r ceptor subfamily 4 group A member 1 (NR4A1), and the
transforming growth factor β (TGFB2) related to angiogenesis, hypoxic response and tu or invasion
were up-regulated.
Regarding the impact of GCD on cancer cell biology, the results evidenced that als in cells treated
with GCD al e the express on of 16 g n s was significantly regulated in comparison to controls,
11 of these genes were down-regulated and five were up-regulat d (Figure 7). As s own in Table 2,
14 common genes were differentially expressed in GCD@DOX or GCD treated c lls in co parison
. Of note, four of these genes encoding for vimentin (VIM), T mor Necrosis Factor (Ligand)
Sup rfamily Me ber 12 (TNFSF12), BicC RNA Binding Protein 1 (BICC1) and Serine/Arginin -Rich
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Protein-Specific Kinase 2 (SRPK2) had an opposite trend in the two treatments. Indeed, the transcript
levels of TNFSF12 and BICC1 were increased by GCD exposure (0.0395 and 0.0386 log2 fold, respectively)
and reduced by GCD@DOX treatment (−0.281 and−0.132 log2 fold, respectively). While, the expression
of VIM and SRPK2 was down-regulated in cells treated with GCD (−0.0134 and −0.0541 log2 fold,
respectively) and up-regulated in cells treated with GCD@DOX (0.0277 and log2 fold, respectively)
(Table 2).
However, in comparison to control cells, the changes induced by treatment with GCD were smaller
than those observed in cells treated with GCD@DOX (see Table 2). For example, the expression of
NR4A1 was increased by 0.5 log2 fold in cell treated with GCD@DOX when compared to control cells,
while the GCD treatment induced an increase of only 0.19 log2 fold in comparison to controls. Similarly,
the expression of TGFβ2 was up-regulated by 0.309 log2 fold in cells treated with GCD@DOX, and by
0.129 log2 fold in cell treated with GCD in comparison to control cells (Table 2).
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Table 2. List of differentially regulated genes in HEp-2 cells treated with GCD@DOX or GCD in
comparison with control cells.
GCD@DOX vs. Ctrl 3 GCD vs. Ctrl
Gene Log2 Fold Change p-Value Log2 Fold Change p-Value
VIM 1 0.0277 0.000813 −0.0134 0.00124
TNFSF12 1 −0.281 0.00145 0.0395 0.00759
NR4A1 0.5 0.00206 0.19 0.004
PLAUR −0.322 0.00286 −0.142 0.00477
GPI −0.187 0.0058
SMURF2 −0.127 0.00774 −0.112 0.00649
ST14 2 −0.597 0.00851
SP1 −0.379 0.0105
ITGB2 2 −0.641 0.011 −0.362 0.0144
BICC1 1 −0.132 0.0128 0.0386 0.0323
TGFβ2 0.309 0.0134 0.129 0.0238
SF3A3 −0.368 0.0144
MAP2K1 −0.225 0.0153 −0.12 0.0212
CLDN3 0.45 0.0164
RBX1 −0.185 0.0194 −0.0617 0.0429
JAG1 2 0.298 0.0214 0.113 0.0416
GSN −0.184 0.0238
AREG 2 0.456 0.0285
SMAD4 −0.174 0.0327
COL1A1 0.226 0.0345
CLDN4 0.278 0.0349
CTSK 2 0.766 0.037
BMP5 −0.358 0.0373
SLC12A6 0.246 0.0385
SMOC1 −0.106 0.0394
WNT5A −0.00843 0.0398 −0.211 0.00117
AKT1 −0.283 0.0423
CNOT10 −0.202 0.0428
HIPK1 0.103 0.0438
ADAP1 −0.23 0.0455
SRPK2 1 0.0604 0.0464 −0.0541 0.0382
SPARC 2 −0.319 0.0464 −0.259 0.0421
NFATC2 −0.194 0.0466
MAPK3 −0.122 0.0481
BRMS1 −0.13 0.0416
DST −0.152 0.0481
1 Gene with an opposite trend in cells treated with GCD@DOX and GCD. 2 Genes with raw count lower than 100
are shown in bold. 3 HEp-2 not treated cells are used as control.
3. Discussion
In this study, we investigated the cellular fate of a new drug delivery system based on graphene
cationic cyclodextrin platform entrapping DOX (GCD@DOX) and the modulation of expression of
some genes related to cancer progression after the cell exposition on graphene materials (GCD and
GCD@DOX). The cellular fate of GCD@DOX was tracked by complementary techniques: FLIM and
Raman mapping investigations emphasized the localization of GCD@DOX complex only in the
cytoplasm (Figures 3 and 4) mainly located in the proximity of the nucleus; whereas microscopy
fluorescence visualized DOX mainly in the nucleus (Figure 5). As a whole, our experiments proved
an efficient cellular uptake of GCD@DOX together with the presence of DOX in the nucleus without
graphene carrier. These findings suggested the release of DOX from GCD@DOX platform adjacent
to perinuclear region and the subsequent nuclear internalization and widespread in the nuclear
compartment. We investigated the cellular fate of GCD@DOX by complementary spectroscopic
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techniques applied directly on murine C26 cell line or on human HEp-2 cell line. Some drawbacks,
such as HEp-2 death events during Raman mapping experiments and the indistinguishable lifetime
signal of free DOX in the cell, hampered the direct tracking of GCD@DOX or its components in human
cell lines by FLIM and Raman mapping.
Cytotoxicity results (Figure 6) evidenced a higher impact on the cell viability of HEp-2 tumor
cells treated with encapsulated DOX respect to ones treated with free drug at the same concentration.
Specifically, a comparable biological outcome (40% of cellular proliferation) was found for loaded DOX
2.5 µg/mL (100 µg/mL of GCD@DOX) and free DOX at 5 µg/mL. This effect could be ascribed to the
peculiar caveolae-mediated endocytosis internalization pathway [16] of GCD that could enhance the
GCD@DOX concentration in the perinuclear region and/or to the synergic effect of graphene (GCD) on
the modulation of gene expression of DOX. From our study, it clearly emerged that tuning of gene
expression profile was induced by GCD or DOX loaded on graphene (GCD@DOX), even if both were
investigated at sub-toxic concentration. The HEp-2 cells were treated with GCD@DOX (25 µg/mL)
or GCD (25 µg/mL) that produced no significant cytotoxicity (cell proliferation of 80% and 100%,
respectively).
Literature data on the gene expression analysis after the exposure to graphene materials is
very limited, and the attention was especially devoted to the impact on the gene involved in
immune responses [18]. Interestingly, graphene oxide (GO) at sub-toxic concentrations has been
reported to compromise plasma membrane and cytoskeleton in J774A.1 macrophages and A549 lung
cancer cells, with no significant cytotoxic effects. Moreover, the interactions of GO with integrins
activated the integrin–FAK–Rho–ROCK pathway, leading to suppression of integrin expression as
well as perturbation of cell membrane and cytoskeleton, and a subsequent cellular priming state [28].
The polyethylene glycol-diamine/R8-functionalized GO has been shown to effectively down-regulate
c-Myc protein and EGFP expression [29]. The treatment with GO-poly-l-lysine hydrobromide/folic
acid (GPF)/DOX/siRNA was able to silence gene expression and inhibit tumors by about 70% without
exhibiting testable cytotoxicity; moreover, there was a decrease of 50% in vascular endothelial
growth factor (VEGF), mRNA, and protein levels [30]. GO nanohybrids, used for the delivery of
chemotherapeutic agent fluorouracil (FU) against breast cancer MCF7 cells, increased the protein levels
of p53 and cleaved PARP proteins [31].
In this paper, we pointed out the importance of looking at the genomic level by using large
genome expression analysis technologies to better understand the impact of graphene materials on
cancer cell biology. Our study revealed that GCD@DOX was able to change the expression of some
genes related to cancer progression, and in most cases, a convergent effect of GCD was detected. It is
important to point out that the cellular response for both materials was observed at concentration that
do not elicit acute cytotoxicity.
In particular, GCD@DOX treatment induced a strong down-regulation of some genes, including
ST14, PLAUR, SP1, SF3A3, ITGB2, GSN, BMP5, TNFSF12, and AKT1, which are involved in the
regulation of the multistep process of cancer development, invasion and metastasis. The modulation of
these genes, except TNFSF12, ITGB2, and PLAUR, is due to DOX effect since no changes were detected
in the cells treated with GCD alone.
Contemporarily, GCD@DOX treatment caused the increase in the expression of CLDN3, NR4A1,
and TGFB2 genes, which may also affect cell response to hypoxic stimuli and epithelial to mesenchymal
transition (EMT). The effect of GCD on NR4A1 and TGFB2 is converging to DOX action. Matriptase,
encoded by ST14 (suppressor of tumorigenicity 14 protein), is known to cleave and activate urokinase
plasminogen activator, and it has been associated with cancer invasion and metastasis of many tumor
types [32]. The urokinase plasminogen activator receptor (uPAR), encoded by Plasminogen Activator,
Urokinase Receptor (PLAUR), has been involved in angiogenesis, growth, and metastasis of many
hematologic and solid tumors, and has recently been shown as a prognostic factor for oral squamous
cell carcinoma [33,34]. SP1 encodes the transcription factor (TF) Sp1, that has been associated with
poor prognosis for various tumors; moreover, functional studies demonstrated that Sp TFs regulate the
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expression of genes responsible for cancer cell growth, survival, migration/invasion, inflammation,
and drug resistance [35]. SF3A3 gene is a component of the spliceosome that represents a useful
therapeutic target in non-small cell lung cancer, since its silencing is associated with induction of cell
cycle arrest and cell death [36].
Gelsolin (GSN) is one of the most abundant actin-binding protein modulating cell motility,
shape and metabolism. Moreover, it participates in immunologic processes through interactions
with different cells of the immune system, and has been recognized as a potential biomarker of
inflammation-related pathological conditions. GSN over expression has been associated with the
progression of oral carcinoma. In addition, several reports indicated GSN as a protein affecting human
colon cancer and melanoma cell motility. A very recent report demonstrated that GSN is able to inhibit
the malignant phenotype of glioblastoma [37–39]. Because of its important role in metastatic processes,
as well as in different cellular mechanisms and cellular interactions, GSN has been suggested as a
potential target for various therapeutic treatments [40].
RAC-alpha serine/threonine-protein kinase 1 (AKT1) is also known to promote metastasis,
but several data reported its ability to inhibit cancer cell invasion [41]. Literature studies revealed
opposite activity of AKT1 in the modulation of cell migration in cells with different origin.
For example, a study on human breast cancer cell lines showed that AKT1 inhibits cell migration
and invasion [42], while using mouse embryonic fibroblasts AKT1 has been found to promote
migration [43]. AKT up-regulation and activation have been associated with increased cellular content
of phosphatidyl-inositol-3-phosphate (PIP3) and phosphatidyl-inositol-3-kinase activity as well as
with increased mRNA and protein amounts of Twist, a transcription factor promoting EMT. Notably,
these effects are inhibited by claudin 3 (CLDN3) and claudin 4 up-regulation [44].
In our work, AKT1 down-regulation was associated with claudin 3 (CLDN3) up-regulation,
thus confirming the aforementioned observations.
CLDN3 belongs to a family of integral membrane proteins forming the backbone of tight junction.
Alterations of CLDN3 gene expression have been frequently observed in several human cancers,
with discordant findings about their role [45]. CLDN3 over-expression has been reported in all subtypes
of epithelial ovarian cancers, and appeared to enhance angiogenic and invasive properties [46]. Also,
in lung adenocarcinoma CLDN3 overexpression resulted in promoting the malignant potential [47].
Conversely, CLDN3 downregulation, frequently reported in human liver cancer, was associated with
a worse prognosis of patients with hepatocellular carcinoma [48]. CLDN3 functions to sustain an
epithelial phenotype and its loss promotes EMT [44].
Conflicting results have also been evidenced for bone morphogenetic protein 5 (BMP5), a member
of the TGFβ family. The loss of BMP5 seems to be an early event in CRC initiation and development,
on the contrary a significant increase of BMP5 positive rate has been found in breast carcinoma in
comparison to normal tissues suggesting that the role of BMP5 varies among tumors [49].
As mentioned above, GCD alone was able to significantly perturbate the expression of some
genes, inducing the down-regulation of and TNFSF12, and the up-regulation of NR4A1 and TGFβ2.
These effects were synergistically reinforced by GCD@DOX.
ITGB2 (Integrin beta-2), also known as leukocyte-specific CD18, plays a key role in cell adhesion
and cell surface signaling, as well as in immune response. ITGB2 expression in cancer cells promotes cell
invasion through the endothelium in leukocyte-like manner. ITGB2 levels are significantly increased
in metastatic prostate cancer [50]. Notably, the observed GCD-induced down-regulation of ITGB2
confirms previously reported effects of graphene on integrin suppression linked to plasma membrane
and cytoskeleton meshwork perturbation [51].
Tumor necrosis factor ligand superfamily member 12 (TNFSF12) is a member of the tumor
necrosis factor superfamily that is also known as TNF-related weak inducer of apoptosis (TWEAK).
TNFSF12 acts through the binding to the receptor Fn14 (fibroblast growth factor-inducible 14),
which in turn triggers the activation of several intracellular signal transduction downstream pathways,
also including those involving tumor necrosis factor, receptor-associated factor and nuclear factor
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kappa B, leading to survival, proliferation, migration, or cell death depending on cell microenvironment.
Indeed, the activation of TWEAK/Fn14 signaling pathways has been shown to promote angiogenesis,
proliferation, EMT, invasion, and migration of tumor cells. Moreover, TWEAK up-regulated expression
has been reported in many solid tumors compared with healthy tissues [51].
A controversial role has been reported for the nuclear receptor subfamily 4 group A member 1
(NR4A1), and transforming growth factor beta 2 (TGFβ2), whose gene expression resulted increased by
GCD@DOX treatment in our study. The role of NR4A1 protein in cancer is also currently unclear. NR4A1
has been found overexpressed in lung, pancreatic, and colon carcinoma, exhibiting a tumor-promoting
effect [52,53]. The up-regulation of NR4A1, detected in both ER-positive and negative breast cancer,
was correlated with a decreased relapse-free survival in breast cancer [54]. Conversely, in human
triple-negative breast cancer the NR4A1 expression was negatively correlated with tumor stage, lymph
node metastasis and disease recurrence, and in mouse models of basal-like mammary tumors a
progressive NR4A1 reduction has been found during cancer development (Nuclear receptor NR4A1 is
a tumor suppressor down-regulated in triple-negative breast cancer).
Members of the TGF-beta family control physiological processes, such as angiogenesis,
cell proliferation, differentiation, adhesion and migration. In particular, it has been hypothesized that
TGFβ2 may have different effects on tumor growth at different stages of the disease, acting as an
inhibitor at the early stages and as activator at the late stages [55,56]; moreover, it has recently been
shown to antagonize IL-6-induced survival and promote cell apoptosis [57].
The increase of VIM expression is correlated to EMT, an event that has been shown to be associated
with resistance and poor outcome treatment in patients with different tumors [58]. Interestingly,
our investigation showed a divergent effect of DOX and GCD on VIM expression; specifically,
the detrimental increase of VIM expression induced by DOX was softened by GCD-induced VIM
down regulation.
GCD@DOX treatment also reversed the down regulating effects of GCD alone on SRPK2 gene.
An oncogenic role of SRPK1/2 (Serine/arginine-protein kinase) was reported in various types of tumors,
including leukemia and melanoma as well as pancreatic, breast, colon, lung, and ovarian cancer [59],
hence different strategies have been proposed for the SRPK1/2 suppression [60]. In our opinion,
the down-regulation of SRPK2 induced by GCD, even if weak, is noteworthy since this GCD ability
may be exploited in the development of SRPK1/2 inhibitor delivery systems in which the graphene can
act in synergy with specific SRPK1/2 inhibitors.
4. Materials and Methods
4.1. Cell Culture
The in vitro study of intracellular uptake and the NanoString® Analysis were performed on
HEp-2 (American Type Culture Collection, ATCC, P.O. Box 1549, Manassas, VA 20108, USA).
The cells were grown in RPMI 1640 medium (Lonza, Group Ltd Muenchensteinerstrasse 38
CH-4002 Basel, Switzerland), supplemented with 10% FBS, 100 U/mL penicillin and 100 µg/mL
streptomycin mixture and were cultured at 37 ◦C in a 5% CO2 incubator. Murine colon carcinoma
cells (C26, Cell Line Service, Germany) were grown in RPMI culture medium (Lonza), supplemented
with 2 mM L-glutamine, penicillin/streptomycin 100 U/mL, 10% fetal calf serum and incubated in
a humidified incubator (37 ◦C, 5% CO2). For Raman imaging, 3 × 104 cells/dish were grown on
Ibidi µ-Dishes (ibidi GmbH Gräfelfing, Germany) with glass bottoms (35 mm, high wall, uncoated).
For FLIM assay, 2 × 105 cells/dish were seeded on Ibidi µ-Dish (50 mm, low wall, ibiTreat coating).
After 24 h of cultivation, the culture medium was replaced with complete culture medium containing
GCD@DOX (15 µg/mL) and incubated for additional 24 h. After incubation, the cells were rinsed with
phosphate buffered saline (PBS) to remove the non-internalized GCD@DOX platforms. Untreated cells
were used as a control sample.
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4.2. Cell Viability Assay
The cell viability of HEp-2 cells treated with GCD@DOX and DOX was determined on the basis
of ATP levels using ViaLightTM plus cell proliferation and cytotoxicity bioassay kit according to the
manufacturer’s instructions (Lonza Group Ltd., Basel, Switzerland). Cells were grown in wells of
96-well plates and treated with different concentrations of GCD@DOX (100 µg/mL, 50 µg/mL and
25 µg/mL) or free DOX (5 µg/mL, 2.5 µg/mL and 1.25 µg/mL). After the indicated incubation time the
cells were harvested and the emitted light intensity related to ATP degradation was quantified with
the GloMax Multi Microplate Luminometer (Promega Corporation, WI, USA). The luminescence value
was converted to the cell proliferation index (%) according to the following equation:
Cell viabillity% = [(A− B)/ (C− B)]% (1)
where A denotes the average luminescence of treated samples, B represents background luminescence
and C represents the average of untreated samples.
4.3. Intracellular Uptake of GCD@DOX
HEp-2 cells were untreated or treated with GCD@DOX (25 µg/mL) for 24 h. DOX was used as a
control (1.25 µg/mL). The samples were collected and washed with warm PBS for twice, fixed with
PFA 4% for 30 min at room temperature and permeabilized with Triton 0.1% for 1 h, covered with a
drop of mounting solution (ProLong™ Diamond Antifade Mountant with DAPI-Invitrogen p36971)
for 30 min in a dark room. The images were captured and processed using confocal laser scanning
microscopy (TCS SP8, Leica, (TCS SP8, Leica Microsystems Srl, Milan, Italy); magnification, 63×.
4.4. Characterization Techniques
Dynamic light scattering (DLS) and ζ-potential measurements were carried out according our
previously reported protocols [16].
A confocal Raman microscope (CRM alpha 300R from WITec GmbH, Ulm, Germany) was
employed to perform the Raman measurements. The Raman measurements on dried droplets of GCD
and GCD@DOX were conducted at a power incident on the samples of 1 mW and the signal was
collected through a 100× objective (NA = 0.9) with an integration time of 10 s for each spectrum.
The 532 nm line of a Nd-YAG was used as excitation. The reference Raman spectrum of DOX powder
was recorded by using an excitation line at 785 nm. The Raman maps of the live C26 colon carcinoma
cells were recorded on the same WITec confocal Raman microscope using the 532 nm line as excitation
wavelength. The Raman signal collected through a W-plan Apochromat 63×water immersion objective
(NA = 1, WD = 2.1 mm, Zeiss, Munich, Germany) was passed through a holographic edge filter and
then focused into a multimode optical fiber of 100 µm diameter which provides the optical pinhole for
confocal measurement. The light emerging from the output optical fiber was analyzed by an ultrahigh
throughput spectrometer equipped with a back-illuminated deep-depletion 1024 × 128-pixel CCD
camera operating at -60 ◦C. The measurements were conducted by choosing an integration time of 0.5 s
for each spectrum. The WITec ProjectPlus software was used for spectral analysis and image processing.
FLIM was performed on a PicoQuant MicroTime 200 (Picoquant GmbH, Berlin Germany) time-resolved
inverted confocal fluorescence microscopy (IX 71, Olympus, Tokyo, Japan) equipped with a Plan N
40×/numerical amperture (NA) = 0.65 objective. The excitation beam was provided via a fiber-coupled,
picosecond diode laser head (LDH-D-C 485, 0.55 µW, PicoQuant) operating at 485 nm (40 MHz).
The signal collected through the objective was spatially and spectrally filtered by a 50 µm diameter
confocal pinhole, long-pass emission filter (HQ485LP, Chroma Technology, Brattleboto, Bellows Falls,
VT, USA) and a photon counting detector module (PDM series, Microphoton devices), connected to a
time-correlated single photon counting (TCSPC) module (PicoHarp 300, PicoQuant, Germany).
All images and time-fluorescence decay curves were acquired and analyzed using the SymPhoTime
software (version 1.6) provided by PicoQuat. For FLIM image acquisition was employed a piezo
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x−y-scanning table and a PiFoc z-piezo actuator for microscope objective. In vitro fluorescence
lifetimes of free DOX and DOX loaded onto the GCD (GCD@DOX) were firstly measured in solution,
and subsequently their internalization into the C26 colon cells were monitored using the FLIM system
well-described above. The spectral response of the GCD@DOX therapeutic platform internalized
inside the cells were also investigated by employing an SR-163 spectrograph equipped with a Newton
970 EMCCD camera from Andor Technology (Belfast, UK), which was attached to an exit port of the
MicroTime 200 optical unit. The integration time used for the acquisition of the emission spectrum
was 60 s. Bright field image of the GCD@DOX treated C26 colon cells scanned by FLIM was acquired
using an Olympus CAM-XC30 digital camera with active Peltier cooling using the same microscope
and an Olympus IX-2 LW UCD (NA = 0.55) condenser.
4.5. Preparation of GCD@DOX
GCD@DOX complex was prepared by mixing 3 mL of GCD dispersion (1 mg/mL) and 1.4 mL of
DOX solution (0.12 mg/mL); the dispersion was sonicated for 20 min by a microtip probe, under bath
ice (UW 2070 SONOPLUS, Bandelin Electronic, (Berlin, Germany) and then it was centrifuged at
5000 RPM for 15 min. The precipitate was washed twice with superpure water up to obtain a colorless
supernatant which was removed. The collected supernatants were analyzed by UV-Vis at 477 nm
absorbance maximum (εDox (477 nm) ≈ 11,500 cm−1 M−1) to estimate the excess of DOX and determine
the actual DOX loading in the complex. The precipitate was lyophilized before the use (recovery
yield of ≈ 40%). The actual DOX loading was of 2.5% and the entrapment efficiency percentage (EE%)
was >95%.
4.6. RNA Isolation and NanoString® Analysis
Total RNA was extracted from HEp-2 cells treated with GCD@DOX (25 µg/mL), GCD (25 µg/mL)
and control cells (in duplicate) using GenElute™ Mammalian Total RNA Miniprep Kit (Sigma
Aldrich, Milan, Italy) according to the manufacturer’s instructions. Total RNA was quantified with
Thermo Scientific™ NanoDrop™ 8000 (Thermo Scientific, Monza, Italy) and stored at −80 ◦C until
expression testing.
RNA transcript amounts were analyzed using NanoString® technology, which allows for direct
multiplexed measurements of gene expression from a low amount of mRNA (25–300 ng) without
the need for cDNA synthesis or PCR. The RNA nCounter PanCancer Human Progression Panel,
which includes 770 genes (angiogenesis, cancer metabolism, extracellular matrix remodeling (ECM),
epithelial-to-mesenchymal transition (EMT), hypoxia, metastasis, tumor growth, tumor invasion and
30 reference genes) was used. Briefly, RNA (100 ng) was hybridized for 16 h using capture and reporter
probes according to the manufacturer’s protocol. Then, the samples were hybridized into the cartridges
using the nCounter Prep Station and digital images from prepped cartridges were processed within
the Nanostring Digital Analyzer. Analysis of read-count data including imaging QC, read-count QC,
and differential expression was performed using the nSolver™ 3.0 with Nanostring Advanced Analysis
Module 2.0 plugin, according to the guidance given by the manufacturer. After applying a negative
control subtraction, raw counts were first normalized with internal controls (Nanostring POS controls)
and with the expression of ten housekeeping genes present in the panel, and then Log2 transformation
was applied to the expression matrix. NanoString data were processed in the R statistical environment.
5. Conclusions
This work investigates the intracellular trafficking in C26 and HEp-2 cells of graphene functionalized
with cationic cyclodextrin (GCD) loaded with the anticancer agent doxorubicin (DOX) and the
related modulation of the expression of some genes involved in cancer biology. The cellular fate
of GCD@DOX was tracked by complementary techniques including FLIM, Raman mapping and
fluorescence microscopy.
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Biological outcomes evidenced the efficient cellular uptake of GCD@DOX and the presence of DOX
in the nucleus without graphene carrier. These findings suggested the release of DOX from GCD@DOX
platform close to perinuclear region and the subsequent nuclear internalization and widespread in the
nuclear compartment. Moreover, cytotoxicity studies showed a higher effect on the cell viability of
tumor HEp-2 cells treated with encapsulated DOX respect to HEp-2 cells treated with free drug at the
same concentration. Probably, the peculiar caveolae-mediated endocytosis internalization pathway of
GCD platform could increase the delivery of DOX into the nucleus, optimizing its biological action.
Overall, NanoString nCounter™ platform, a novel digital molecular barcoding technology,
provided evidence for 34 (out of 700) differentially expressed cancer-related genes in cells treated with
GCD@DOX compared with untreated cells (16 in cells treated with GCD alone). Given the different
roles in tumor biology of the aforementioned proteins and considering the small number of genes
significantly modified by GCD@DOX treatment, it is not possible to identify a distinct molecular
pathway activated or inhibited by GCD@DOX. Therefore, the present findings are not conclusive
of GCD@DOX effectiveness against HEp-2 cell growth and invasiveness, and are worthy of further
studies. However, data obtained by gene expression analysis provide useful information on the
impact of graphene materials on cancer cell biology and may guide further efforts towards effective
graphene-based drug delivery systems. This study unveiled the ability of GCD to sensitize cancer cells
to chemotherapeutic drugs (i.e., DOX); therefore, chemotherapy efficacy can be enhanced by GCD
co-treatment. Finally, we point out that the positive or negative effects related to down/up-regulation
of genes involved in cancer metastasis and progression were detected at doses that do not elicit acute
cytotoxicity. Further investigations will be performed to obtain information about the regulation
of gene expression in response to changing the time of exposure and the concentration of the drug
delivery system.
Author Contributions: The manuscript was written through contributions of all authors. A.P. and M.T.S.
supervised the project and wrote the paper. A.P., A.M., A.S., and M.T.S. developed the concepts. G.N. synthesized
graphene materials. A.M. and R.Z. carried out UV−vis, fluorescence emission, DLS, and ζ-potential measurements.
C.R., M.F., M.P. and S.A. carried out FLIM and Raman, analyses. R.P. and M.M.-P. performed cell uptake
experiments. D.C., M.C., E.A.M.V. and R.I. performed the gene expression analyses. All authors discussed the
results and commented on the manuscript. All authors have read and agreed to the published version of
the manuscript.
Funding: This work was aided by a grant from University of Messina, Research & Mobility 2016 Project (project
code: RES AND MOB 2016 Sciortino).
Acknowledgments: We are grateful to Jayakumar Vadakekolathy- John Van Geest Cancer Research Centre, Schoolof
Science & Technology, Nottingham Trent University, Nottingham, United Kingdom for the NanoString analyses.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to
publish the results.
Abbreviations
G Graphene
GCD Graphene modified with cationic cyclodextrins
DOX Doxorubicin
GCD@DOX Graphene cationic cyclodextrin platform entrapping doxorubicin
DLS Dynamic light scattering
FLIM Fluorescence lifetime imaging microscopy
TEM Transmission electron microscope
HEp-2 cells Human epithelial type 2 cells
ECM Extracellular matrix
ST14 Matriptase
ITGB2 Integrin-beta2
JAG1 Jagged 1
AREG Amphiregulin
CTSK Cathepsin K
Int. J. Mol. Sci. 2020, 21, 4891 16 of 19
SPARC Osteonectin
GSN Gelsolin
BMP5 Bone morphogenetic protein 5
AKT1 Serine/Threonine Kinase 1
CLDN3 Claudin-3
NR4A1 Nuclear receptor subfamily 4 group A member 1
TGFβ2 Transforming growth factor β
VIM Vimentin
TNFSF12 Tumor Necrosis Factor (Ligand) Superfamily Member 12
BICC1 BicC RNA Binding Protein 1
SRPK2 Serine/Arginine-Rich Protein-Specific Kinase 2
References
1. Orecchioni, M.; Cabizza, R.; Bianco, A.; Delogu, L.G. Graphene as cancer theranostic tool: Progress and
future challenges. Theranostics 2015, 5, 710–723. [CrossRef] [PubMed]
2. Barreca, D.; Neri, G.; Scala, A.; Fazio, E.; Gentile, D.; Rescifina, A.; Piperno, A. Covalently immobilized
catalase on functionalized graphene: Effect on the activity, immobilization efficiency, and tetramer stability.
Biomater. Sci. 2018, 6, 3231–3240. [CrossRef] [PubMed]
3. Cordaro, A.; Neri, G.; Sciortino, M.T.; Scala, A.; Piperno, A. Graphene-based strategies in liquid biopsy and
in viral diseases diagnosis. Nanomaterials 2020, 10, 1014. [CrossRef] [PubMed]
4. Li, J.; Liang, X.; Zhang, J.; Yin, Y.; Zuo, T.; Wang, Y.; Yang, X.; Shen, Q. Inhibiting pulmonary metastasis
of breast cancer based on dual-targeting graphene oxide with high stability and drug loading capacity.
Nanomed. Nanotechnol. Biol. Med. 2018, 14, 1237–1248. [CrossRef]
5. Xu, X.; Wang, J.; Wang, Y.; Zhao, L.; Li, Y.; Liu, C. Formation of graphene oxide-hybridized nanogels for
combinative anticancer therapy. Nanomed. Nanotechnol. Biol. Med. 2018, 14, 2387–2395. [CrossRef] [PubMed]
6. Gonçalves, M.; Mignani, S.; Rodrigues, J.; Tomás, H. A glance over doxorubicin based-nanotherapeutics:
From proof-of-concept studies to solutions in the market. J. Control. Release 2020, 317, 347–374. [CrossRef]
7. Zhao, H.; Ding, R.; Zhao, X.; Li, Y.; Qu, L.; Pei, H.; Yildirimer, L.; Wu, Z.; Zhang, W. Graphene-based
nanomaterials for drug and/or gene delivery, bioimaging, and tissue engineering. Drug Discov. Today 2017,
22, 1302–1317. [CrossRef]
8. Li, Y.; Gao, X.; Yu, Z.; Liu, B.; Pan, W.; Li, N.; Tang, B. Reversing multidrug resistance by multiplexed gene
silencing for enhanced breast cancer chemotherapy. ACS Appl. Mater. Interfaces 2018, 10, 15461–15466.
[CrossRef]
9. Piperno, A.; Scala, A.; Mazzaglia, A.; Neri, G.; Pennisi, R.; Sciortino, M.T.; Grassi, G. Cellular signaling
pathways activated by functional graphene nanomaterials. Int. J. Mol. Sci. 2018, 19, 3365. [CrossRef]
10. Martín, C.; Kostarelos, K.; Prato, M.; Bianco, A. Biocompatibility and biodegradability of 2d materials:
Graphene and beyond. Chem. Commun. 2019, 55, 5540–5546. [CrossRef]
11. Loeian, M.S.; Mehdi Aghaei, S.; Farhadi, F.; Rai, V.; Yang, H.W.; Johnson, M.D.; Aqil, F.; Mandadi, M.; Rai, S.N.;
Panchapakesan, B. Liquid biopsy using the nanotube-ctc-chip: Capture of invasive ctcs with high purity
using preferential adherence in breast cancer patients. Lab Chip 2019, 19, 1899–1915. [CrossRef] [PubMed]
12. Neri, G.; Scala, A.; Fazio, E.; Mineo, P.G.; Rescifina, A.; Piperno, A.; Grassi, G. Repurposing of oxazolone
chemistry: Gaining access to functionalized graphene nanosheets in a top-down approach from graphite.
Chem. Sci. 2015, 6, 6961–6970. [CrossRef] [PubMed]
13. Tan, E.; Li, B.L.; Ariga, K.; Lim, C.-T.; Garaj, S.; Leong, D.T. Toxicity of two-dimensional layered materials
and their heterostructures. Bioconj. Chem. 2019, 30, 2287–2299. [CrossRef] [PubMed]
14. Neri, G.; Scala, A.; Barreca, F.; Fazio, E.; Mineo, P.G.; Mazzaglia, A.; Grassi, G.; Piperno, A. Engineering
of carbon based nanomaterials by ring-opening reactions of a reactive azlactone graphene platform.
Chem. Commun. 2015, 51, 4846–4849. [CrossRef] [PubMed]
15. Neri, G.; Micale, N.; Scala, A.; Fazio, E.; Mazzaglia, A.; Mineo, P.G.; Montesi, M.; Panseri, S.; Tampieri, A.;
Grassi, G.; et al. Silibinin-conjugated graphene nanoplatform: Synthesis, characterization and biological
evaluation. FlatChem 2017, 1, 34–41. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4891 17 of 19
16. Piperno, A.; Mazzaglia, A.; Scala, A.; Pennisi, R.; Zagami, R.; Neri, G.; Torcasio, S.M.; Rosmini, C.; Mineo, P.G.;
Potara, M.; et al. Casting light on intracellular tracking of a new functional graphene-based microrna delivery
system by flim and raman imaging. ACS Appl. Mater. Interfaces 2019, 11, 46101–46111. [CrossRef]
17. Yazdimamaghani, M.; Moos, P.J.; Ghandehari, H. Time- and dose-dependent gene expression analysis of
macrophage response as a function of porosity of silica nanoparticles. Nanomed. Nanotechnol. Biol. Med.
2019, 21, 102041. [CrossRef]
18. Orecchioni, M.; Jasim, D.A.; Pescatori, M.; Manetti, R.; Fozza, C.; Sgarrella, F.; Bedognetti, D.; Bianco, A.;
Kostarelos, K.; Delogu, L.G. Molecular and genomic impact of large and small lateral dimension graphene
oxide sheets on human immune cells from healthy donors. Adv. Healthc. Mater. 2016, 5, 276–287. [CrossRef]
19. Orecchioni, M.; Bedognetti, D.; Newman, L.; Fuoco, C.; Spada, F.; Hendrickx, W.; Marincola, F.M.; Sgarrella, F.;
Rodrigues, A.F.; Ménard-Moyon, C.; et al. Single-cell mass cytometry and transcriptome profiling reveal the
impact of graphene on human immune cells. Nat. Commun. 2017, 8, 1109. [CrossRef]
20. de Lázaro, I.; Kostarelos, K. Exposure to graphene oxide sheets alters the expression of reference genes used
for real-time rt-qpcr normalization. Sci. Rep. 2019, 9, 12520. [CrossRef]
21. Farahani, M.; Rezaei-Tavirani, M.; Zali, H.; Hatamie, S.; Ghasemi, N. Systems toxicology assessment revealed
the impact of graphene-based materials on cell cycle regulators. J. Biomed. Mater. Res. Part A 2020, 108,
1520–1533. [CrossRef] [PubMed]
22. Kasprzak, A.; Poplawska, M. Recent developments in the synthesis and applications of graphene-family
materials functionalized with cyclodextrins. Chem. Comm. 2018, 54, 8547–8562. [CrossRef] [PubMed]
23. Choudhary, P.; Parandhaman, T.; Ramalingam, B.; Duraipandy, N.; Kiran, M.S.; Das, S.K. Fabrication of
nontoxic reduced graphene oxide protein nanoframework as sustained antimicrobial coating for biomedical
application. ACS Appl. Mater. Interfaces 2017, 9, 38255–38269. [CrossRef] [PubMed]
24. Neri, G.; Fazio, E.; Mineo, P.G.; Scala, A.; Piperno, A. Sers sensing properties of new graphene/gold
nanocomposite. Nanomaterials 2019, 9, 1236. [CrossRef] [PubMed]
25. Farhane, Z.; Bonnier, F.; Casey, A.; Byrne, H.J. Raman micro spectroscopy for in vitro drug screening:
Subcellular localisation and interactions of doxorubicin. Analyst 2015, 140, 4212–4223. [CrossRef]
26. Schneckenburger, H.; Wagner, M.; Weber, P.; Strauss, W.S.L.; Sailer, R. Autofluorescence lifetime imaging of
cultivated cells using a uv picosecond laser diode. J. Fluoresc. 2004, 14, 649–654. [CrossRef]
27. Yang, F.; Teves, S.S.; Kemp, C.J.; Henikoff, S. Doxorubicin, DNA torsion, and chromatin dynamics.
Biochim. Biophys. Acta BBA Rev. Cancer 2014, 1845, 84–89. [CrossRef]
28. Zhu, J.; Xu, M.; Gao, M.; Zhang, Z.; Xu, Y.; Xia, T.; Liu, S. Graphene oxide induced perturbation to plasma
membrane and cytoskeletal meshwork sensitize cancer cells to chemotherapeutic agents. ACS Nano 2017, 11,
2637–2651. [CrossRef]
29. Imani, R.; Prakash, S.; Vali, H.; Faghihi, S. Polyethylene glycol and octa-arginine dual-functionalized
nanographene oxide: An optimization for efficient nucleic acid delivery. Biomater. Sci. 2018, 6, 1636–1650.
[CrossRef]
30. Sun, Q.; Wang, X.; Cui, C.; Li, J.; Wang, Y. Doxorubicin and anti-vegf sirna co-delivery via nano-graphene
oxide for enhanced cancer therapy in vitro and in vivo. Int. J. Nanomed. 2018, 13, 3713–3728. [CrossRef]
31. Ashjaran, M.; Babazadeh, M.; Akbarzadeh, A.; Davaran, S.; Salehi, R. Stimuli-responsive polyvinylpyrrolidone-
nippam-lysine graphene oxide nano-hybrid as an anticancer drug delivery on mcf7 cell line. Artif. Cell.
Nanomed. B. 2019, 47, 443–454. [CrossRef] [PubMed]
32. Emmanouilidi, A.; Paladin, D.; Greening, D.W.; Falasca, M. Oncogenic and non-malignant pancreatic
exosome cargo reveal distinct expression of oncogenic and prognostic factors involved in tumor invasion
and metastasis. Proteomics 2019, 19, 1800158. [CrossRef] [PubMed]
33. Mazar, A.P. Urokinase plasminogen activator receptor choreographs multiple ligand interactions: Implications
for tumor progression and therapy. Clin. Cancer Res. 2008, 14, 5649. [CrossRef] [PubMed]
34. Wang, J.; Wang, Y.; Kong, F.; Han, R.; Song, W.; Chen, D.; Bu, L.; Wang, S.; Yue, J.; Ma, L. Identification of
a six-gene prognostic signature for oral squamous cell carcinoma. J. Cell. Physiol. 2020, 235, 3056–3068.
[CrossRef]
35. Safe, S.; Abbruzzese, J.; Abdelrahim, M.; Hedrick, E. Specificity protein transcription factors and cancer:
Opportunities for drug development. Cancer Prev. Res. 2018, 11, 371. [CrossRef]
Int. J. Mol. Sci. 2020, 21, 4891 18 of 19
36. Siebring-van Olst, E.; Blijlevens, M.; de Menezes, R.X.; van der Meulen-Muileman, I.H.; Smit, E.F.;
van Beusechem, V.W. A genome-wide sirna screen for regulators of tumor suppressor p53 activity in
human non-small cell lung cancer cells identifies components of the rna splicing machinery as targets for
anticancer treatment. Mol. Oncol. 2017, 11, 534–551. [CrossRef]
37. Deng, R.; Hao, J.; Han, W.; Ni, Y.; Huang, X.; Hu, Q. Gelsolin regulates proliferation, apoptosis, migration
and invasion in human oral carcinoma cells. Oncol. Lett. 2015, 9, 2129–2134. [CrossRef]
38. Chen, Z.; Li, K.; Yin, X.; Li, H.; Li, Y.; Zhang, Q.; Wang, H.; Qiu, Y. Lower expression of gelsolin in colon
cancer and its diagnostic value in colon cancer patients. J. Cancer 2019, 10, 1288–1296. [CrossRef]
39. Zhang, J.; Furuta, T.; Sabit, H.; Tamai, S.; Jiapaer, S.; Dong, Y.; Kinoshita, M.; Uchida, Y.; Ohtsuki, S.;
Terasaki, T.; et al. Gelsolin inhibits malignant phenotype of glioblastoma and is regulated by mir-654-5p and
mir-450b-5p. Cancer Sci. 2020. [CrossRef]
40. Feldt, J.; Schicht, M.; Garreis, F.; Welss, J.; Schneider, U.W.; Paulsen, F. Structure, regulation and related
diseases of the actin-binding protein gelsolin. Expert Rev. Mol. Med. 2019, 20, e7. [CrossRef]
41. Rao, G.; Pierobon, M.; Kim, I.K.; Hsu, W.H.; Deng, J.; Moon, Y.W.; Petricoin, E.F.; Zhang, Y.W.; Wang, Y.;
Giaccone, G. Inhibition of akt1 signaling promotes invasion and metastasis of non-small cell lung cancer
cells with k-ras or egfr mutations. Sci. Rep. 2017, 7, 7066. [CrossRef] [PubMed]
42. Yoeli-Lerner, M.; Yiu, G.K.; Rabinovitz, I.; Erhardt, P.; Jauliac, S.; Toker, A. Akt blocks breast cancer cell
motility and invasion through the transcription factor nfat. Mol. Cell 2005, 20, 539–550. [CrossRef] [PubMed]
43. Zhou, G.-L.; Tucker, D.F.; Bae, S.S.; Bhatheja, K.; Birnbaum, M.J.; Field, J. Opposing roles for akt1 and akt2 in
rac/pak signaling and cell migration. J. Biol. Chem. 2006, 281, 36443–36453. [CrossRef] [PubMed]
44. Lin, X.; Shang, X.; Manorek, G.; Howell, S.B. Regulation of the epithelial-mesenchymal transition by claudin-3
and claudin-4. PLoS ONE 2013, 8, e67496. [CrossRef]
45. Hewitt, K.J.; Agarwal, R.; Morin, P.J. The claudin gene family: Expression in normal and neoplastic tissues.
BMC Cancer 2006, 6, 186. [CrossRef]
46. Agarwal, R.; Souza, T.; Morin, P.J. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances
invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res. 2005, 65, 7378–7385.
[CrossRef]
47. Zhang, L.; Wang, Y.; Zhang, B.; Zhang, H.; Zhou, M.; Wei, M.; Dong, Q.; Xu, Y.; Wang, Z.; Gao, L.; et al.
Claudin-3 expression increases the malignant potential of lung adenocarcinoma cells: Role of epidermal
growth factor receptor activation. Oncotarget 2017, 8, 23033–23047. [CrossRef]
48. Jiang, L.; Yang, Y.D.; Fu, L.; Xu, W.; Liu, D.; Liang, Q.; Zhang, X.; Xu, L.; Guan, X.Y.; Wu, B.; et al. Cldn3 inhibits
cancer aggressiveness via wnt-emt signaling and is a potential prognostic biomarker for hepatocellular
carcinoma. Oncotarget 2014, 5, 7663–7676. [CrossRef]
49. Chen, E.; Yang, F.; He, H.; Li, Q.; Zhang, W.; Xing, J.; Zhu, Z.; Jiang, J.; Wang, H.; Zhao, X.; et al. Alteration of
tumor suppressor bmp5 in sporadic colorectal cancer: A genomic and transcriptomic profiling based study.
Mol. Cancer 2018, 17, 176. [CrossRef]
50. Liu, H.; Dai, X.; Cao, X.; Yan, H.; Ji, X.; Zhang, H.; Shen, S.; Si, Y.; Zhang, H.; Chen, J.; et al. Prdm4 mediates
yap-induced cell invasion by activating leukocyte-specific integrin β2 expression. EMBO Rep. 2018, 19,
e45180. [CrossRef]
51. Hu, G.; Zeng, W.; Xia, Y. Tweak/fn14 signaling in tumors. Tumor Biol. 2017, 39, 1010428317714624. [CrossRef]
[PubMed]
52. Lee, S.O.; Li, X.; Khan, S.; Safe, S. Targeting nr4a1 (tr3) in cancer cells and tumors. Expert Opin. Ther. Targets
2011, 15, 195–206. [CrossRef]
53. Zhu, B.; Yang, J.R.; Jia, Y.; Zhang, P.; Shen, L.; Li, X.L.; Li, J.; Wang, B. Overexpression of nr4a1 is associated
with tumor recurrence and poor survival in non-small-cell lung carcinoma. Oncotarget 2017, 8, 113977–113986.
[CrossRef] [PubMed]
54. Hedrick, E.; Lee, S.O.; Doddapaneni, R.; Singh, M.; Safe, S. Nuclear receptor 4a1 as a drug target for breast
cancer chemotherapy. Endocr. Relat. Cancer 2015, 22, 831–840. [CrossRef] [PubMed]
55. Bierie, B.; Moses, H.L. Tgfβ: The molecular jekyll and hyde of cancer. Nat. Rev. Cancer 2006, 6, 506–520.
[CrossRef]
56. Bierie, B.; Moses, H.L. Transforming growth factor beta (tgf-β) and inflammation in cancer. Cytokine Growth
F. R. 2010, 21, 49–59. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2020, 21, 4891 19 of 19
57. Du, Y.; Sun, J.; Liu, X.; Nan, J.; Qin, X.; Wang, X.; Guo, J.; Zhao, C.; Yang, J. Tgf-β2 antagonizes il-6-promoted
cell survival. Mol. Cell. Biochem. 2019, 461, 119–126. [CrossRef]
58. Herreño, A.M.; Ramírez, A.C.; Chaparro, V.P.; Fernandez, M.J.; Cañas, A.; Morantes, C.F.; Moreno, O.M.;
Brugés, R.E.; Mejía, J.A.; Bustos, F.J.; et al. Role of runx2 transcription factor in epithelial mesenchymal
transition in non-small cell lung cancer: Epigenetic control of the runx2 p1 promoter. Tumor Biol. 2019, 41,
1010428319851014. [CrossRef]
59. Prattapong, P.; Ngernsombat, C.; Aimjongjun, S.; Janvilisri, T. Crispr/cas9-mediated double knockout of
srpk1 and srpk2 in a nasopharyngeal carcinoma cell line. Cancer Rep. 2020, 3, e1224. [CrossRef]
60. Hatcher, J.M.; Wu, G.; Zeng, C.; Zhu, J.; Meng, F.; Patel, S.; Wang, W.; Ficarro, S.B.; Leggett, A.L.;
Powell, C.E.; et al. Srpkin-1: A covalent srpk1/2 inhibitor that potently converts vegf from pro-angiogenic to
anti-angiogenic isoform. Cell Chem. Biol. 2018, 25, 460–470.e466. [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
